Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non Operating Income (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Other Non Operating Income for 11 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 351.58% to -$2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.0 million, a 431.68% decrease, with the full-year FY2025 number at -$2.0 million, down 431.68% from a year prior.
  • Other Non Operating Income was -$2.0 million for Q4 2025 at Cartesian Therapeutics, down from -$5000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $508000.0 in Q1 2024 to a low of -$2.0 million in Q4 2025.
  • A 5-year average of -$88375.0 and a median of $27000.0 in 2022 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: plummeted 1933.33% in 2023, then surged 8433.33% in 2024.
  • Cartesian Therapeutics' Other Non Operating Income stood at $494000.0 in 2021, then crashed by 92.11% to $39000.0 in 2022, then tumbled by 1933.33% to -$715000.0 in 2023, then soared by 37.9% to -$444000.0 in 2024, then plummeted by 351.58% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Other Non Operating Income are -$2.0 million (Q4 2025), -$5000.0 (Q2 2025), and -$444000.0 (Q4 2024).